H.C Wainwright Asserts Buy Stance as ImmunityBio, Inc. (IBRX) Achieves Positive Results on Bladder Cancer Treatment

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best penny stocks to buy for 2026. On December 16, ImmunityBio, Inc. (NASDAQ:IBRX) delivered positive clinical trial results for its ANKTIVA plus BCG treatment. The candidate drug being trialed in high-grade papillary non-muscle invasive bladder cancer demonstrated strong long-term efficacy in patients.

The trial results showed 96% disease-specific survival and 83% progression-free survival at 36 months. The study also demonstrated high cystectomy-avoidance rates of 92% at 12 months and 82% at 36 months. The positive clinical trial results are a significant milestone, given that there are few treatment options for invasive bladder cancer, with cystectomy considered the definitive treatment.

“Prolongation of progression-free survival, disease-specific free survival and avoidance of bladder removal are clinically meaningful goals of next-generation chemotherapy-free immunotherapy. Our findings provide evidence that ANKTIVA plus BCG would offer a novel and efficacious treatment option for these patients,” said lead author Sam S. Chang, M.D., Professor of Urology and Chief Surgical Officer of the Vanderbilt Ingram Cancer Center.

Meanwhile, H.C. Wainwright analyst Andres Y. Maldonado has reiterated a Buy rating on the stock and set an $8 price target. The positive rating is in response to the European Medicines Agency’s positive opinion and recommendation for authorization for AKTIVA in combination with BCG.

ImmunityBio, Inc. (NASDAQ:IBRX) is a vertically integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases.

While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.